FDA mandates increased warnings for epilepsy drugs, stops short of issuing black box

The U.S. FDA has issued new labelling guidelines for drugs used in the treatment of epilepsy. The agency has announced that the directive is relevant for all anti-epileptic drugs, including those for treating psychiatric disorders, migraine headaches, and other conditions.

Read the full article here